Faculty of Medicine of Lazarski University in Warsaw, Poland.
Pol Merkur Lekarski. 2022 Aug 23;50(298):262-263.
COPD is one of the risk factors for contracting COVID-19. Good management of patients, appropriate treatment with inhaled preparations, including inhaled glucocorticosteroids, with simultaneous monitoring concomitant infections, and the use of vaccinations allow to reduce the risk of developing COVID-19. At the same time, it is necessary to limit the performance of spirometric tests to reduce the probability of SARS-CoV-2 infection. In the case of a confirmed infection, it is necessary to continue basic treatment, with strict adherence to the recommended dosage of drugs, which may significantly protect the patient against post-inflammatory fibrosis in the pulmonary parenchyma.
COPD 是感染 COVID-19 的风险因素之一。通过对患者进行良好的管理，使用吸入制剂（包括吸入性糖皮质激素）进行适当治疗，同时监测伴随感染，并使用疫苗，可以降低感染 COVID-19 的风险。同时，有必要限制进行肺量测定检查，以降低 SARS-CoV-2 感染的概率。在确诊感染的情况下，有必要继续进行基础治疗，严格遵守药物推荐剂量，这可以显著保护患者免受肺部实质炎症后纤维化的影响。
